Related references
Note: Only part of the references are listed.Multi-OMICS study of a CHCHD10 variant causing ALS demonstrates metabolic rewiring and activation of endoplasmic reticulum and mitochondrial unfolded protein responses
Isabella R. Straub et al.
HUMAN MOLECULAR GENETICS (2021)
Serum creatine kinase and creatinine in adult spinal muscular atrophy under nusinersen treatment
Maren Freigang et al.
ANNALS OF CLINICAL AND TRANSLATIONAL NEUROLOGY (2021)
Loss of mitochondrial protein CHCHD10 in skeletal muscle causes neuromuscular junction impairment
Yatao Xiao et al.
HUMAN MOLECULAR GENETICS (2020)
Neurofilament light chain in serum of adolescent and adult SMA patients under treatment with nusinersen
Claudia D. Wurster et al.
JOURNAL OF NEUROLOGY (2020)
Nusinersen treatment and cerebrospinal fluid neurofilaments: An explorative study on Spinal Muscular Atrophy type 3 patients
Irene Faravelli et al.
JOURNAL OF CELLULAR AND MOLECULAR MEDICINE (2020)
Serum creatinine is a biomarker of progressive denervation in spinal muscular atrophy
Christiano R. R. Alves et al.
NEUROLOGY (2020)
Transmembrane protease serine 5: a novel Schwann cell plasma marker for CMT1A
Hongge Wang et al.
ANNALS OF CLINICAL AND TRANSLATIONAL NEUROLOGY (2020)
Notame: Workflow for Non-Targeted LC-MS Metabolic Profiling
Anton Klavus et al.
METABOLITES (2020)
ALS and Parkinson's disease genes CHCHD10 and CHCHD2 modify synaptic transcriptomes in human iPSC-derived motor neurons
Sandra Harjuhaahto et al.
NEUROBIOLOGY OF DISEASE (2020)
Muscle and not neuronal biomarkers correlate with severity in spinal and bulbar muscular atrophy
Vittoria Lombardi et al.
NEUROLOGY (2019)
NFL is a marker of treatment response in children with SMA treated with nusinersen
Bob Olsson et al.
JOURNAL OF NEUROLOGY (2019)
Neurofilament light chain as a biomarker in neurological disorders
Lorenzo Gaetani et al.
JOURNAL OF NEUROLOGY NEUROSURGERY AND PSYCHIATRY (2019)
Nusinersen initiated in infants during the presymptomatic stage of spinal muscular atrophy: Interim efficacy and safety results from the Phase 2 NURTURE study
Darryl C. De Vivo et al.
NEUROMUSCULAR DISORDERS (2019)
Mitochondrial defect in muscle precedes neuromuscular junction degeneration and motor neuron death in CHCHD10S59L/+ mouse
Emmanuelle C. Genin et al.
ACTA NEUROPATHOLOGICA (2019)
ALS/FTD mutant CHCHD10 mice reveal a tissue-specific toxic gain-of-function and mitochondrial stress response
Corey J. Anderson et al.
ACTA NEUROPATHOLOGICA (2019)
Neurochemical markers in CSF of adolescent and adult SMA patients undergoing nusinersen treatment
Claudia D. Wurster et al.
THERAPEUTIC ADVANCES IN NEUROLOGICAL DISORDERS (2019)
Plasma neurofilament light chain concentration in the inherited peripheral neuropathies
Asa Sandelius et al.
NEUROLOGY (2018)
Neurofilaments as biomarkers in neurological disorders
Michael Khalil et al.
NATURE REVIEWS NEUROLOGY (2018)
Loss of MICOS complex integrity and mitochondrial damage, but not TDP-43 mitochondrial localisation, are likely associated with severity of CHCHD10-related diseases
Emmanuelle C. Genin et al.
NEUROBIOLOGY OF DISEASE (2018)
Metabolomes of mitochondrial diseases and inclusion body myositis patients: treatment targets and biomarkers
Jana Buzkova et al.
EMBO MOLECULAR MEDICINE (2018)
Neurofilament markers for ALS correlate with extent of upper and lower motor neuron disease
Koen Poesen et al.
NEUROLOGY (2017)
CHCHD10 mutations promote loss of mitochondrial cristae junctions with impaired mitochondrial genome maintenance and inhibition of apoptosis
Emmanuelle C. Genin et al.
EMBO MOLECULAR MEDICINE (2016)
Distinct Muscle Biopsy Findings in Genetically Defined Adult-Onset Motor Neuron Disorders
Manu Jokela et al.
PLOS ONE (2016)
Impaired muscle uptake of creatine in spinal and bulbar muscular atrophy
Yasuhiro Hijikata et al.
ANNALS OF CLINICAL AND TRANSLATIONAL NEUROLOGY (2016)
GDF15 is a novel biomarker to evaluate efficacy of pyruvate therapy for mitochondrial diseases
Yasunori Fujita et al.
MITOCHONDRION (2015)
Neurofilament light chain A prognostic biomarker in amyotrophic lateral sclerosis
Ching-Hua Lu et al.
NEUROLOGY (2015)
Late Onset Spinal Motor Neuronopathy Is Caused by Mutation in CHCHD10
Sini Penttila et al.
ANNALS OF NEUROLOGY (2015)
Mutation in the novel nuclear-encoded mitochondrial protein CHCHD10 in a family with autosomal dominant mitochondrial myopathy
Senda Ajroud-Driss et al.
NEUROGENETICS (2015)
CHCHD10 variant p.(Gly66Val) causes axonal Charcot-Marie-Tooth disease
Mari Auranen et al.
NEUROLOGY-GENETICS (2015)
Two novel mutations in conserved codons indicate that CHCHD10 is a gene associated with motor neuron disease
Kathrin Mueller et al.
BRAIN (2014)
A mitochondrial origin for frontotemporal dementia and amyotrophic lateral sclerosis through CHCHD10 involvement
Sylvie Bannwarth et al.
BRAIN (2014)
Late-onset spinal motor neuronopathy - A common form of dominant SMA
Sini Penttila et al.
NEUROMUSCULAR DISORDERS (2014)
Reliability of the CMT neuropathy score (second version) in Charcot-Marie-Tooth disease
Sinead M. Murphy et al.
JOURNAL OF THE PERIPHERAL NERVOUS SYSTEM (2011)
FGF-21 as a biomarker for muscle-manifesting mitochondrial respiratory chain deficiencies: a diagnostic study
Anu Suomalainen et al.
LANCET NEUROLOGY (2011)
Late-onset lower motor neuronopathy A new autosomal dominant disorder
M. Jokela et al.
NEUROLOGY (2011)
A plasma signature of human mitochondrial disease revealed through metabolic profiling of spent media from cultured muscle cells
Oded Shaham et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2010)
Diagnostic accuracy of blood lactate-to-pyruvate molar ratio in the differential diagnosis of congenital lactic acidosis
Francois-Guillaume Debray et al.
CLINICAL CHEMISTRY (2007)
Share Paper
